BENZTROPINE MESYLATE

Post-LOE

benztropine mesylate

Hikma

ANDAINJECTIONINJECTABLE

Approved

Aug 2009

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

BENZTROPINE MESYLATE (benztropine mesylate) by Hikma is cli n ical pharmacology benztropine mesylate possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism. Approved for of extrapyramidal disorders (except tardive dyskinesia — see ) due to neuroleptic drugs (e. First approved in 2009.

Drug data last refreshed Yesterday

Mechanism of Action

CLI N ICAL PHARMACOLOGY Benztropine mesylate possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism. In the isolated guinea pig ileum, the anticholinergic activity of this drug is…

Indications (1)

of extrapyramidal disorders (except tardive dyskinesia — see ) due to neuroleptic drugs (e

Company

Worked on BENZTROPINE MESYLATE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.